Cargando…

Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study

INTRODUCTION: Atopic dermatitis (AD) is an incurable, inflammatory skin disease characterized by skin barrier disruption and immune dysregulation. Although AD is considered a childhood disease, adult onset is possible, presenting with daily sleep disturbance and functional impairment associated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Falissard, Bruno, Simpson, Eric L., Guttman-Yassky, Emma, Papp, Kim A., Barbarot, Sebastien, Gadkari, Abhijit, Saba, Grece, Gautier, Laurene, Abbe, Adeline, Eckert, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090107/ https://www.ncbi.nlm.nih.gov/pubmed/32006346 http://dx.doi.org/10.1007/s13555-020-00356-0

Ejemplares similares

The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada
por: de Bruin‐Weller, M., et al.
Publicado: (2020)

Successful use of ustekinumab therapy in refractory severe atopic dermatitis
por: Shroff, Anjali, et al.
Publicado: (2014)

Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics
por: Mansouri, Yasaman, et al.
Publicado: (2015)

Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis
por: Simpson, Eric, et al.
Publicado: (2019)

A possible role for IL-17A in establishing Th2 inflammation in murine models of atopic dermatitis
por: Dhingra, Nikhil, et al.
Publicado: (2014)

The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment
por: Facheris, Paola, et al.
Publicado: (2023)

Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches
por: Moyle, Matthew, et al.
Publicado: (2019)

Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
por: Kuznik, Andreas, et al.
Publicado: (2017)

Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2019)

Mechanisms of contact sensitization offer insights into the role of barrier defects versus intrinsic immune abnormalities as drivers of atopic dermatitis
por: Dhingra, Nikhil, et al.
Publicado: (2013)

Burden of atopic dermatitis in Japanese adults: Analysis of data from the 2013 National Health and Wellness Survey
por: Arima, Kazuhiko, et al.
Publicado: (2018)

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial
por: Simpson, Eric L., et al.
Publicado: (2019)

Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Responder Threshold for Patient-Oriented Eczema Measure (POEM) and Children’s Dermatology Life Quality Index (CDLQI) in Adolescents with Atopic Dermatitis
por: Simpson, Eric L., et al.
Publicado: (2019)

The Use of Real-World Data to Evaluate the Association Between Atopic Dermatitis and Cardiovascular Disease: A Retrospective Claims Analysis
por: Wu, Jashin J., et al.
Publicado: (2021)

Impact of vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the atopic dermatitis serum proteome
por: Kim, Madeline, et al.
Publicado: (2023)

Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers
por: He, Helen, et al.
Publicado: (2020)

Development, Psychometric Validation and Responder Definition of Worst Itch Scale in Children with Severe Atopic Dermatitis
por: Paller, Amy S., et al.
Publicado: (2022)

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial
por: Guttman-Yassky, Emma, et al.
Publicado: (2020)

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
por: Bansal, Ashish, et al.
Publicado: (2021)

Effects of variations in access to care for children with atopic dermatitis
por: Siegfried, Elaine C., et al.
Publicado: (2020)

Changes in Skin and Nasal Microbiome and Staphylococcal Species Following Treatment of Atopic Dermatitis with Dupilumab
por: Olesen, Caroline Meyer, et al.
Publicado: (2021)

Priority research questions in atopic dermatitis: an International Eczema Council eDelphi consensus
por: Abuabara, K., et al.
Publicado: (2021)

Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity
por: Vekaria, Anjali S., et al.
Publicado: (2017)

Social Media Platforms Listening Study on Atopic Dermatitis: Quantitative and Qualitative Findings
por: Voillot, Paméla, et al.
Publicado: (2022)

The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins
por: Brunner, Patrick M., et al.
Publicado: (2017)

Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset
por: Eichenfield, Lawrence F., et al.
Publicado: (2022)

Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate‐to‐severe disease
por: Sims, Jonathan T., et al.
Publicado: (2021)

International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale
por: Abuabara, Katrina, et al.
Publicado: (2020)

Prevention of atopic dermatitis
por: Williams, Hywel C., et al.
Publicado: (2012)

COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab
por: Ungar, Benjamin, et al.
Publicado: (2022)

Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement
por: Drucker, A.M., et al.
Publicado: (2018)

Author Correction: The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins
por: Brunner, Patrick M., et al.
Publicado: (2018)

ΔNp63 regulates IL-33 and IL-31 signaling in atopic dermatitis
por: Rizzo, J M, et al.
Publicado: (2016)

The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis
por: Ungar, Benjamin, et al.
Publicado: (2022)

Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis
por: Yosipovitch, G., et al.
Publicado: (2019)

Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways
por: Ewald, David A., et al.
Publicado: (2015)

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
por: Simpson, Eric L., et al.
Publicado: (2021)

Stopping Antidepressants and Anxiolytics as Major Concerns Reported in Online Health Communities: A Text Mining Approach
por: Abbe, Adeline, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qu13ce7arre541lcr0ocbb5lrk